Search Result "KRAS wild type"
Cetuximab/Irinotecan-Chemotherapy in KRAS Wild-type Pretreated Metastatic Colorectal Cancer: A Pooled Analysis and Review of Literature.
Journal: Reviews on Recent Clinical Trials
Volume: 8 Issue: 2 Year: 2013 Page: 101-109
Author(s): Sandro Barni,Mara Ghilardi,Karen Borgonovo,Mary Cabiddu,Alberto Zaniboni,Fausto Petrelli
Targeting Mutant KRAS for Anticancer Therapy
Journal: Current Topics in Medicinal Chemistry
Volume: 19 Issue: 23 Year: 2019 Page: 2098-2113
Author(s): Fengqian Chen,Martin P. Alphonse,Yan Liu,Qi Liu
KRAS: A Promising Therapeutic Target for Cancer Treatment
Journal: Current Topics in Medicinal Chemistry
Volume: 19 Issue: 23 Year: 2019 Page: 2081-2097
Author(s): Hai-Zhou Wu,Jia-Qi Xiao,Song-Shu Xiao,Yan Cheng
KRAS Pathways: A Potential Gateway for Cancer Therapeutics andDiagnostics
Journal: Recent Patents on Anti-Cancer Drug Discovery
Volume: 19 Issue: 3 Year: 2024 Page: 268-279
Author(s): Pankaj Kumar Tripathi,Khushi R. Mittal,Chakresh Kumar Jain
Cetuximab Inhibits Gastric Cancer Growth in vivo, Independent of KRAS Status
Journal: Current Cancer Drug Targets
Volume: 14 Issue: 2 Year: 2014 Page: 217-224
Author(s): Min Shi,Hailong Shi,Jun Ji,Qu Cai,Xuehua Chen,Yingyan Yu,Bingya Liu,Zhenggang Zhu,Jun Zhang
Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Journal: Current Topics in Medicinal Chemistry
Volume: 19 Issue: 23 Year: 2019 Page: 2158-2175
Author(s): Winfrey Pui Yee Hoo,Pui Yan Siak,Lionel L.A. In
Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers
Journal: Current Topics in Medicinal Chemistry
Volume: 19 Issue: 23 Year: 2019 Page: 2128-2142
Author(s): Hao He,Chang Xu,Zhao Cheng,Xiaoying Qian,Lei Zheng
Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 12 Issue: 2 Year: 2012 Page: 163-171
Author(s): Tomoya Yokota
Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC.
Journal: Reviews on Recent Clinical Trials
Volume: 8 Issue: 2 Year: 2013 Page: 93-100
Author(s): Paolo Maione,Assunta Sgambato,Antonio Rossi,Paola Claudia Sacco,Maria Anna Bareschino,Clorinda Schettino,Francesca Casaluce,Fortunato Ciardiello,Cesare Gridelli
EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo
Journal: Current Cancer Drug Targets
Volume: 17 Issue: 1 Year: 2017 Page: 89-97
Author(s): Chenfei Zhou,Liangjun Zhu,Jun Ji,Fangmi Ding,Chao Wang,Qu Cai,Yingyan Yu,Zhenggang Zhu,Jun Zhang